Kidney Diseases: Health Services

(asked on 29th November 2024) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to improve access to treatment to manage (a) chronic kidney disease and (b) common complications to help slow the progression of the disease.


Answered by
Andrew Gwynne Portrait
Andrew Gwynne
Parliamentary Under-Secretary (Department of Health and Social Care)
This question was answered on 9th December 2024

NHS England is working to detect people at risk of kidney disease through the NHS Health Check Programme. The programme, which is available for everyone between the ages of 40 and 74 years old who is not already on a chronic disease register, assesses people’s health and risk of developing certain health problems. Using this information, patients are supported to make behavioural changes and access treatment which helps to prevent and detect kidney disease earlier.

The NHS Long Term Plan has committed to a number of key ambitions to improve care and outcomes for individuals with cardiovascular disease (CVD), including enhanced diagnostic support in the community, better personalised planning, and increasing access to cardiac rehabilitation. These ambitions will support the delivery of the aim to help prevent 150,000 heart attacks, strokes, and dementia cases by 2029. Specific priorities include the management of CVD risk factors, such as hypertension, or high blood pressure, atrial fibrillation, or an abnormal, fast irregular heartbeat, and high cholesterol, ensuring early and rapid access to diagnostic tests and treatment. NHS England is working to identify opportunities for improved integration of CVD management across clinical specialities.

The UK National Screening Committee (UK NSC) reviewed chronic kidney disease (CKD) and glomerulonephritis in 2011, concluding that a population-wide screening programme would not be recommended. Although the UK NSC has not since looked at the evidence for a targeted programme, it can be alerted to any new published peer-reviewed evidence which may suggest the case for a new screening programme. Further information is available at the following link:

https://www.gov.uk/government/publications/uk-nsc-annual-call-submitting-a-screening-proposal/uk-nsc-annual-call-how-to-submit-a-proposal

The National Health Service provides access to tests and therapies to diagnose, code, and treat patients with early-stage CKD. NHS England, through the Renal Services Transformation Programme and regional renal networks, is implementing initiatives to provide better, integrated care, reduce health inequalities, and focus on prevention and timely intervention for kidney disease within both primary and secondary care. Regional renal clinical networks prioritise CKD diagnosis and prevention within their transformation ambitions, facilitating earlier treatment. This includes considerations to develop a unified approach to testing populations at risk of developing CKD, and includes raising awareness of diagnostic tools like urine albumin creatinine tests, enabling CKD diagnosis at stages 1 and 2. NHS England aims to improve awareness and access to these important urine and blood tests across primary and secondary care. In addition, the transformation programme launched a renal toolkit last year for use by systems, that outlines principles to support better management of patients identified with CKD throughout their patient journey.

The National Institute for Health and Care Excellence (NICE) guidance, Chronic kidney disease: Assessment and management [NG203], updated in November 2021, sets out best practice for clinicians in the diagnosis and management of CKD. The guidance covers the care and treatment of patients at risk of CKD. It includes recommendations on the monitoring of patients at risk of CKD and aims to prevent or delay the progression of the disease. The guidance is available at the following link:

https://www.nice.org.uk/guidance/ng203

The management of CKD has evolved over the last two decades. Increasingly, there are drug interventions to slow the progression of kidney disease, mitigate the risk of cardiovascular events associated with CKD, and reduce the additional risk of acute kidney injury. NICE guidance continues to be updated as evidence accumulates, and NHS England, through the Renal Clinical Reference Group, supports that process through advice and horizon scanning, as therapeutic interventions are introduced. The renal clinical networks have all established work examining the management of CKD, including diagnosis and intervention.

Reticulating Splines